StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for PTHS yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-19 | $26.14 | $27.00 | +3.29% | 0.1M |
| 05-20 | $27.06 | $27.11 | +0.18% | 0.1M |
| 05-21 | $27.12 | $27.10 | -0.07% | 0.0M |
| 05-22 | $26.29 | $26.66 | +1.41% | 0.0M |
| 05-26 | $26.09 | $27.50 | +5.40% | 0.0M |
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q1 2025 2025-03-31 |
|---|---|---|---|---|
Revenue | $10.91M | $16.80M | $294.00K | $0.00 |
Operating Income | $-13.09M | $-32.43M | $-20.43M | $-1.83M |
Net Income | $-10.24M | $-43.32M | $-21.66M | $-1.97M |
EPS (Diluted) | $-3.09 | $-23.04 | $-14.96 | $-3.21 |
Total Assets | $145.38M | $130.40M | $126.43M | $911.18K |
Total Liabilities | $110.28M | $91.52M | $68.18M | $5.11M |
Cash & Equivalents | $31.98M | $17.97M | $14.20M | $131.00K |
Free Cash Flow OCF − CapEx | $-13.32M | $-22.69M | Not available | $-632.00K |
Shares Outstanding | 3.37M | 3.23M | 3.09M | 6.18M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.